Mosapride, a selective serotonin 5-HT4 receptor agonist, and alogliptin, a selective dipeptidyl peptidase-4 inhibitor, exert synergic effects on plasma active GLP-1 levels and glucose tolerance in mice

• Mosapride citrate slightly increased plasma GLP-1 levels independent of feeding.
• Mosapride citrate plus alogliptin enhanced the increases in active GLP-1 levels.
• Mosapride citrate plus alogliptin improved glucose tolerance.
• The 5-HT4 receptor agonist and DPP-4 inhibitor exert synergic effects.

Pharmacologic stimulation of serotonin 5-HT4 receptors increased plasma active glucagon-like-peptide-1 (GLP-1) levels independent of feeding, and that pharmacologic stimulation of 5-HT4 receptors and pharmacologic inhibition of dipeptidyl peptidase-4 exerted synergic effects on plasma active GLP-1 levels and glucose tolerance in mice.